Christopher Perry > Orrick, Herrington & Sutcliffe (UK) LLP > London, England > Lawyer Profile

Orrick, Herrington & Sutcliffe (UK) LLP
107 CHEAPSIDE
LONDON
EC2V 6DN
England

Work Department

Venture Capital, M&A

Position

Managing Associate

Career

Chris advises on a wide variety of corporate law issues affecting early to late-stage technology and life sciences companies and those who invest in them. He is recognised as a “Recommended Individual” for Venture Capital in the Legal 500 UK 2023.

With a significant investor-side practice, Chris has extensive experience advising market leading investors including Kinnevik, VNV, VEF, Amadeus, Coatue, Paypal, Updata, Lightrock, Sony Innovation Fund and Salesforce Ventures with a focus on UK, pan-European and US centred transactions along with a growing practice in emerging markets.

Chris has represented a wide variety of companies at all stages of the growth lifecycle, ranging from early-stage startups to unicorn companies. Chris has a particular focus on intellectual property rich sectors including life sciences, fintech, SaaS and artificial intelligence.

Chris regularly works on complex cross-border transactions (based upon both BVCA and NVCA style documents) and is familiar with a wide variety of transaction structures including tranched financings and ratchets. In addition to equity financing rounds, Chris advises clients on other corporate transactions including bridge financings, secondary transactions, venture debt, cross-border flip transactions and group reorganisations.

As part of a market leading team, Chris works with his colleagues to provide the full breadth of legal services to technology and life science companies including commercial and customer agreements, intellectual property and employment arrangements.

Prior to joining Orrick, Chris trained and worked at a major international law firm where he advised on several large M&A transactions as well as a number of private equity and venture capital investments.

Education

  • University of Warwick, B.A., Law and Business Studies, 2013, First Class
  • BPP Law School, Legal Practice Course, 2014, Distinction

Lawyer Rankings

London > Corporate and commercial > Venture capital

(Rising stars)

Christopher PerryOrrick, Herrington & Sutcliffe (UK) LLP

Best-known for its investee offering but increasingly active for funds throughout the investment life cycle, Orrick, Herrington & Sutcliffe (UK) LLP provides ‘supremely knowledgeable and commercial’ advice and an ‘updated view on what is “market”‘, by dint of the sheer volume of transactions handled by the practice in the technology sector. Drawing upon the expertise of several US-qualified lawyers in its London office, as well as benefiting from a market-leading Silicon Valley offering in the US, the team has ‘a unique perspective in understanding US investor needs’ on their inbound investments and is also well-placed to represent investee companies seeking to scale up and to access the US capital markets as an exit strategy. The ‘extremely knowledgeable’ Jamie Moore excels in handing cross-border mandates for investors and high growth technology companies, and has ‘a unique ability to translate UK concepts for US investors’. Drawing upon strong connections within the venture capital ecosystem, including with venture capitalists, angel investors, and industry experts, Ylan Steiner remains pivotal to the firm’s increasingly well-established investor offering and ‘is well-versed in areas such as fundraising for companies at all stages’. A ‘very reassuring’ presence on deals, ‘given his market knowledge and reputation’, Jamie Moore combines deep sector knowledge in disruptive technologies, including fintech and AI, with a highly commercial mindset on transactional work, ensuring that he is a popular choice for investees in the space throughout the investment life cycle. Senior associate Christopher Perryis able to clearly explain concepts/changes and proposed amendments in an effort to keep things moving’, and is gaining market recognition among technology and life sciences companies, as well as those investing in them. Christopher Grew heads the team.